ClinicalTrials.Veeva

Menu

Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine (VOR-IISR)

Mass General Brigham logo

Mass General Brigham

Status and phase

Terminated
Phase 4

Conditions

Major Depression
Depression, Unipolar
Depression
Depressive Disorder

Treatments

Drug: Vortioxetine

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT02969876
2016P001243

Details and patient eligibility

About

The study is a 6-week, proof-of-concept, open trial of vortioxetine for 20 patients with major depressive disorder.

Full description

The U.S. Food and Drug Administration approved vortioxetine to treat major depressive disorder in 2013. Researchers believe vortioxetine may improve pattern separation and pattern completion (i.e., a neurological function) in people with major depressive disorder; thus, this research study aims to determine how vortioxetine increases a person's ability to think. The current study is an open label trial, therefore, all participants will receive vortioxetine. Furthermore, participants receive the vortioxetine at no cost. It will take participants 6 weeks to complete this study. Participants are asked to come to the Mass General Hospital campus for 1 screening visit which includes a full psychiatric evaluation, and 5 additional study visits. During study visits, participants will meet with a clinician and then complete computer based cognitive tests.

Enrollment

2 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Meets Diagnostic and Statistical Manual of Mental Disorders (Versions 4 and 5) criteria for and Major Depressive Disorder.
  2. Hamilton Depression Rating Scale-17 score greater than 18.
  3. Men and women between ages >=18 and 65.

Exclusion criteria

  1. Meets Diagnostic and Statistical Manual of Mental Disorders (versions 4 and 5) criteria for schizophrenia, schizoaffective disorder, obsessive compulsive disorder.

  2. Unable to follow instructions or otherwise unable to participate in the trial.

  3. Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (defined as oral contraceptive pill or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, partner with vasectomy)

  4. Patients who, in the investigator's judgment, pose a current, serious suicidal or homicidal risk.

  5. Serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease.

  6. History of seizure disorder.

  7. The following Diagnostic and Statistical Manual of Mental Disorders (Version 4) diagnoses (any current or past history, except substance abuse disorders):

    Organic mental disorders, schizoaffective disorder, delusional disorder, psychotic disorders not elsewhere classified.

  8. History of multiple adverse drug reactions or allergy to the study drugs.

  9. Patients with mood congruent or mood incongruent psychotic features

  10. Current use of other psychotropic drugs.

  11. Clinical or laboratory evidence of hypothyroidism.

  12. Patients who have failed to respond during the course of their current major depressive episode to at least one adequate antidepressant trial, defined as six weeks or more of treatment with citalopram 40 mg/day (or its antidepressant equivalent)

  13. Patients who have had electroconvulsive therapy within the 6 months preceding baseline.

  14. Concomitant use of serotonergic agents

  15. Meets Diagnostic and Statistical Manual of Mental Disorders (versions 4 and 5) criteria for bipolar disorder

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

2 participants in 1 patient group

Study Phase
Other group
Description:
During this phase participants receive open label vortioxetine for 6 weeks. Participants come to the Depression Clinical \& Research Program at the Massachusetts General Hospital for visits once a week. During these visits the participants meet with clinicians and complete cognitive tasks.
Treatment:
Drug: Vortioxetine

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems